{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:28:58Z","timestamp":1774949338264,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.lungcan.2015.10.013","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:47:22Z","timestamp":1445554042000},"page":"614-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Romana E.","family":"Mikes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hutarew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-7018","authenticated-orcid":false,"given":"Michael","family":"Studnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lungcan.2015.10.013_bib0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2015.10.013_bib0010","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-11-2109","article-title":"Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR\/KRAS and presence of PIK3CA\/AKT1 mutations","volume":"18","author":"Rekhtman","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2015.10.013_bib0015","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-11-2370","article-title":"Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities","volume":"18","author":"Perez-Moreno","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2015.10.013_bib0020","doi-asserted-by":"crossref","first-page":"e40109","DOI":"10.1371\/journal.pone.0040109","article-title":"Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status","volume":"7","author":"An","year":"2012","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.lungcan.2015.10.013_bib0025","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2015.10.013_bib0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/JTO.0b013e3182111461","article-title":"Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors","volume":"6","author":"Koh","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.10.013_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2466-14-83","article-title":"Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2015.10.013_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.10.006","article-title":"Major partial response to crizotinib, a dual MET\/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement","volume":"83","author":"Schwab","year":"2014","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2015.10.013_bib0045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T09:25:51Z","timestamp":1537262751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215300829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0169500215300829"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.10.013","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}